TWC
SPRO icon

TD Waterhouse Canada’s Spero Therapeutics SPRO Stock Holding History

TD Waterhouse Canada’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-300
Closed -$456 – 1814
2023
Q1 		$456 Hold
300
– – ﹤0.01% 1652
2022
Q4 		$522 Sell
300
-200
-40% -$373 ﹤0.01% 1608
2022
Q3 		$1K Hold
500
– – ﹤0.01% 1578
2022
Q2 		$410 Hold
500
– – ﹤0.01% 1674
2022
Q1 		$3.54K Hold
500
– – ﹤0.01% 1515
2021
Q4 		$7.45K Buy
+500
New +$7.94K ﹤0.01% 1390

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TD Waterhouse Canada's SPRO Position: Q2 2023 in Review

TD Waterhouse Canada sold out of Spero Therapeutics (SPRO) in Q2 2023, closing a stake of 300 shares — an estimated $456 sold.

TD Waterhouse Canada first reported a position in SPRO in Q4 2021 and held it in 6 quarters. The position peaked at $7.45K in Q4 2021. 56 funds tracked by Wall St. Rank hold SPRO as of Q2 2023.

  • TD Waterhouse Canada reported no remaining Spero Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TD Waterhouse Canada sold 300 Spero Therapeutics shares in Q2 2023, an estimated $456.
  • TD Waterhouse Canada first reported a position in Spero Therapeutics in Q4 2021 and held it in 6 quarters.
  • TD Waterhouse Canada's Spero Therapeutics position peaked at $7.45K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2023.

Based on TD Waterhouse Canada's 13F filing for Q2 2023, filed 13 Nov 2023.